This study is designed to demonstrate the efficacy and safety of vildagliptin compared to metformin in elderly drug naive patients with type 2 diabetes
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
335
Investigative Centers
Nuremberg, Germany
Novartis Pharmaceuticals
Basel, Switzerland
Change from baseline in HbA1c
Time frame: after 24 weeks of treatment
Adverse event profile
Time frame: after 24 weeks of treatment
Gastrointestinal tolerability
Time frame: after 24 weeks of treatment
Patients with endpoint HbA1c <7% and patients with reduction in HbA1c > 0.7%
Time frame: after 24 weeks of treatment
Change from baseline in fasting plasma glucose
Time frame: after 24 weeks of treatment
Change from baseline in body weight
Time frame: after 24 weeks of treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.